Hepatocellular carcinoma (HCC) is generally observed as a massive tumor originated from one lobe in *** is the treatment of choice in dogs with a massive HCC. However,complete resection is technically difficult in the...
详细信息
Hepatocellular carcinoma (HCC) is generally observed as a massive tumor originated from one lobe in *** is the treatment of choice in dogs with a massive HCC. However,complete resection is technically difficult in the cases with an extremely enlarged HCC pressing or involving the large vessels such as caudal vena cava and main hepatic veins. This study aimed to report the divisional hepatic lobectomy for complete resection of very large HCC and successful treatment of paraneoplastic hypoglycemic seizures in a dog.A 12-year-old spayed Yorkshire terrier was referred to our hospital with chief complaints of seizures and a very large hepatic mass. In the first presentation,serum liver enzymes levels increased,and serum glucose concentration was 29mg/dl. Computed tomography (CT) angiography revealed that a huge mass occurred in the right medial,quadrate,and left medial hepatic lobes and flattened caudal vena cava and main portal vein. The patient underwent surgical *** mass was approached with midline celiotomy,caudal median sternotomy,and bilateral paracostal laparotomy. En bloc resection of central and left divisional lobes including the mass was accomplished with surgical ligation of hepatic hilar vessels and hepatic veins. The hypoglycemic seizures were postoperatively resolved,and no clinical signs were *** hypoglycemic seizures were thought to be associated with the insulin-like growth factors (IGF). The right divisional lobes could serve the sufficient hepatic function. Divisional hepatic lobectomy based on CT angiography is very useful for the treatment of canine HCCs.
Rituximab is currently used not only in the treatment of B-cell lymphoma but also for various other diseases, including autoimmune diseases, post-transplant graft vs host disease, and rejection following kidney transp...
详细信息
Rituximab is currently used not only in the treatment of B-cell lymphoma but also for various other diseases, including autoimmune diseases, post-transplant graft vs host disease, and rejection following kidney transplants. Due to rituximab's widespread use, great progress has been made regarding research into complications that arise from its use, one of the most serious being the reactivation of hepatitis B virus(HBV), and efforts continue to establish guidelines for preventive treatment against this occurrence. This report discusses preventive measures against rituximab-induced HBV reactivation and future objectives.
暂无评论